Cancer Immunotherapy Market Size to grow by USD 45.5 billion between 2024-2028
According to a research report “ Cancer Immunotherapy Market” by Type (Monoclonal antibodies, Check point inhibitors and immunomodulators, Cancer vaccines) Application (Lung cancer, Breast cancer, Colorectal cancer, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 45.5 billion, at a CAGR of 8.1% during the forecast period. In the business world, the rising incidence of cancer is a significant concern, with an estimated 20 million new cases and 9.7 million deaths reported globally by the World Health Organization in 2022. Lung cancer, caused by unhealthy lifestyle choices such as smoking and poor diet, as well as environmental factors, was the most common cancer, accounting for 12.4% of all new cases (2.5 million). Colon cancer, with 9.6% of new cases (1.9 million), followed closely behind. These statistics underscore the urgent need for preventative measures and innovative treatments in the cancer immunotherapy market.
Browse market data tables, figures, and in-depth TOC on “Cancer Immunotherapy Market” by Type (Monoclonal antibodies, Check point inhibitors and immunomodulators, Cancer vaccines) Application (Lung cancer, Breast cancer, Colorectal cancer, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Type, the Monoclonal antibodies segment is projected to dominate the market size in 2024
In the global cancer landscape, lung cancer continues to pose a significant challenge due to the high prevalence of tobacco smoking, which accounts for the majority of cases, particularly non-small cell lung cancer (NSCLC). Despite ongoing public health initiatives and tobacco control policies, smoking rates remain elevated in numerous regions, leading to a persistent increase in lung cancer incidence. However, the therapeutic landscape is evolving with the emergence of immunotherapy as a promising treatment modality for certain types of lung cancer. Notable immune checkpoint inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, have demonstrated durable responses and enhanced survival rates in advanced or metastatic NSCLC patients. The ongoing research and development in immunotherapy are expanding the treatment options for lung cancer patients, thereby driving the growth of the global cancer immunotherapy market during the forecast period.
By Application, Lung cancer segment is expected to hold the largest market size for the year 2024
The Cancer Immunotherapy Market represents a significant growth opportunity for businesses, driven by the increasing prevalence of cancer and the advancement of innovative treatments. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, offer promising solutions for improving patient outcomes and survival rates. Market expansion is further fueled by collaborations between industry leaders and research institutions, as well as regulatory approvals for new therapies. Businesses must seize this moment to capitalize on the potential of cancer immunotherapy and contribute to the ongoing fight against this disease.
North America is forecasted to hold the largest market size by region in 2024
The cancer immunotherapy market represents a significant growth opportunity for businesses, driven by the increasing prevalence of cancer and the advancement of innovative treatments. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, offer promising solutions for enhancing patient outcomes and reducing side effects compared to traditional chemotherapy and radiation. Market expansion is further fueled by collaborations between industry players and research institutions, regulatory approvals, and reimbursement policies.
The Cancer Immunotherapy Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Cancer Immunotherapy Market has witnessed significant growth in recent years due to the development of innovative treatments for various types of cancer. Multiple myeloma patients have benefited from advancements such as Blinatumomab and Keytruda, which are used in combination with traditional therapy. CAR-T cell therapy, a type of immunotherapy, has shown promising results in the treatment of acute myeloid leukemia and other cancers. Companies like Immatics are working on developing new therapies, such as FLT3-targeting agents like quizartinib, to enhance the immune response against cancer cells. Hospital Pharmacies play a crucial role in the administration of these advanced therapies, including mAbs, checkpoint inhibitors, and cancer vaccines. Biosimilars of these drugs are also entering the market, providing cost-effective alternatives. Immunomodulators and targeted therapies continue to be key players in the market, with prostate, head & neck, breast, melanoma, colorectal, and lungs cancer being major indications. The future of cancer treatment lies in the combination of traditional and immunotherapies to maximize therapeutic efficacy.
Market Research Overview
The Cancer Immunotherapy Market is witnessing significant growth due to the development of innovative therapies such as Repotrectinib, a selective TRK inhibitor, and Laherparepvec Talimogene, an oncolytic viral therapy. Other key players in the market include Sipuleucel-T, a cell-based immunotherapy for prostate cancer, and CAR-T cell therapies like Blinatumomab and Keytruda. Oncolytic Viral Therapies, which use man-made proteins to selectively target and destroy cancer cells, are also gaining popularity. Immunotherapies, including Checkpoint Inhibitors, Monoclonal Antibodies, and Immune Response Modulators, are revolutionizing cancer treatment. Durvalumab, an anti-PD-L1 mAb, is used for treating multiple myeloma and bladder cancer. Financial burden remains a challenge, with the high cost of these therapies leading some patients to turn to online pharmacies or hospital pharmacies for access. Traditional therapies like Radiation therapy and Chemotherapies continue to be used, but Target Therapies and Cancer Vaccines are becoming increasingly important. Bioinformatics tools are being used to analyze genetic data and develop personalized treatment plans. Key players in the market include Immatics, developing FLT3-targeted therapies for acute myeloid leukemia, and Quizartinib, a FLT3 inhibitor. Cancer Research Centers, Clinics, and Hospitals worldwide are at the forefront of developing and delivering these innovative therapies for Breast Cancer, Head & Neck Cancer, Melanoma, Colorectal Cancer, and Lung Cancer. Biosimilars are also entering the market, providing more affordable options for patients. The future of cancer treatment lies in the continued development of these immunotherapies and the integration of technology to improve patient outcomes.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
